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Neuropathic pain is a chronic secondary pain condition, which is a consequence of peripheral or central nervous (somatosensory)
system lesions or diseases. It is a devastating condition, which aﬀects around 7% of the general population. Numerous etiological
factors contribute to the development of chronic neuropathic pain. It can originate from the peripheral part of the nervous system
such as in the case of trigeminal or postherpetic neuralgia, peripheral nerve injury, painful polyneuropathies, or radiculopathies.
Central chronic neuropathic pain can develop as a result of spinal cord or brain injury, stroke, or multiple sclerosis. As ﬁrst-line
pharmacological treatment options, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids
are recommended. In trigeminal neuralgia, carbamazepine and oxcarbazepine are the ﬁrst-choice drugs. In drug-refractory
cases, interventional, physical, and psychological therapies are available. This review was structured based on a PubMed search
of papers published in the ﬁeld from 2010 until May 2019.
1. Introduction
The current deﬁnition of neuropathic pain (NP) was released
almost one decade ago by the International Association for
the Study of Pain (IASP) [1]. Based on this statement, NP is
caused by a lesion or disease of the somatosensory (periph-
eral and/or central) nervous system. This special type of pain
aﬀects some 7-10% of the general population globally, pre-
dominantly in patients above 50 years of age [2]. The charac-
teristics of NP are clearly distinct from those of nociceptive
pain, which together represent the two fundamental groups
of pain conditions. However, according to a new mixed pain
concept, an additional group of pain disorders is proposed,
which is referred to as “nociplastic pain” [3]. Chronic NP
includes peripheral and central NP conditions [4].
A substantial advancement in this ﬁeld is the latest
classiﬁcation of these heterogeneous pain syndromes,
published by the IASP in 2019 [5]. The subtypes of chronic
peripheral NP are the following: trigeminal neuralgia (TN),
chronic NP after peripheral nerve injury, painful polyneuro-
pathy, postherpetic neuralgia, and painful radiculopathy. The
following forms belong to chronic central NP: chronic
central NP associated with spinal cord injury (SCI), chronic
central NP associated with brain injury, chronic central post-
stroke pain, and chronic central NP associated with multiple
sclerosis (MS) [4] (Tables 1 and 2). In general, NP conditions
are underrecognized, underdiagnosed, and undertreated.
Treating NP is a real challenge for physicians. The
management of NP targets predominantly the clinical
symptoms instead of the causative factors. Currently available
treatment options include both pharmacological and
nonpharmacological approaches.
Regarding pharmacological therapies in NP, tricyclic
antidepressants (TCA; e.g., amitriptyline), serotonin-
norepinephrine reuptake inhibitors (SNRIs; i.e., duloxetine
and venlafaxine), and gabapentinoids (i.e., gabapentin and
pregabalin) are recommended as ﬁrst-line treatments. In
second-line, weak opioid analgesics (e.g., tramadol and
tapentadol) are recommended. Topical agents (i.e., lidocaine
plaster and capsaicin patch) are recommended as second-
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line pharmacological treatments exclusively in peripheral
NP. As third-line drugs, strong opioids (e.g., morphine and
oxycodone) are recommended both in central and periph-
eral NP conditions, whereas botulinum toxin type A-
haemagglutinin complex (BoNTA) can be recommended
only in peripheral NP conditions. In TN, carbamazepine
(CBZ) and oxcarbazepine (OXC) are the ﬁrst-choice drugs.
Nonpharmacological therapeutic options for drug-
refractory NP include the following approaches: interven-
tional therapies (e.g., peripheral nerve blockade, epidural
steroid injection, sympathetic nerve/ganglion treatment,
intrathecal drug/medication delivery, and peripheral and
central neurostimulation), physical therapies (e.g., massage,
ultrasound, transcutaneous electrical nerve stimulation
(TENS), laser, and mirror therapy exercise training), and
psychological therapies (cognitive behavioural therapy
(CBT), psychotherapy, and internet-delivered psychological
therapies).
Papers selected for this work were searched by PubMed
with the keywords: “peripheral neuropathic pain”, “central
neuropathic pain”, “trigeminal neuralgia”, “chronic neuro-
pathic pain after peripheral nerve injury”, “painful
polyneuropathy”, “postherpetic neuralgia”, “painful radicu-
lopathy”, “chronic central neuropathic pain associated with
spinal cord injury”, “chronic central neuropathic pain associ-
ated with brain injury”, “chronic central post-stroke pain”, or
“chronic central neuropathic pain associated with multiple
sclerosis” and “therapy”, “treatment”, “pharmacological”,
“non-pharmacological”, “investigational therapy”, “physical
therapy”, or “psychological therapy”. Only abstracts
published in English were considered. The PubMed search
was done for papers published from 2010 until May 2019.
The aim of this review was to provide an expert view
summarizing the current status of available therapeutic
possibilities both in peripheral and central NP conditions,
based on the novel IASP classiﬁcation system of chronic
NP conditions. An additional goal was to present the results
of the clinical trials of nonpharmacological approaches in
diﬀerent types of drug-refractory NP.
2. Chronic Peripheral NP
2.1. Trigeminal Neuralgia. According to the new concept of
classiﬁcation of chronic pain by the IASP, TN is classiﬁed
as a subclass of “chronic peripheral NP”; however, it has
“chronic secondary headaches and orofacial pains” as an
additional parent [4].
The deﬁnition of TN is based on the diagnostic criteria of
the latest classiﬁcation of the International Headache Society
(ICHD-3) [6, 7]. This is a devastating pain condition charac-
terized by recurrent unilateral orofacial ache restricted to one
or more branches of the trigeminal nerve. The characteristics
of the pain can be described as electric shock-like, shooting,
stabbing, or sharp in quality and severe in intensity. The
painful attacks last from a couple of seconds to a maximum
2 minutes. This painful paroxysm can be triggered by innoc-
uous mechanical stimuli or orofacial movements. Even more,
in some cases, involuntary painful contractions of the
muscles on the face can occur, as it was referred to by the
previous term “tic douloureux.”
TN is a subtype of painful cranial neuropathies and is
divided to classical, secondary, and idiopathic forms. Painful
trigeminal neuropathy is classiﬁed as a diﬀerent entity [6–8].
The essence of classical TN is that the patients have
Table 1: The IASP classiﬁcation of chronic pain [35].
Chronic pain
Chronic primary pain syndromes Chronic secondary pain syndromes
Chronic widespread pain Chronic cancer-related pain
Complex regional pain syndrome Chronic postsurgical or posttraumatic pain
Chronic NP
Chronic primary headache or orofacial pain Chronic secondary headache or orofacial pain
Chronic primary visceral pain Chronic secondary visceral pain
Chronic primary musculoskeletal pain Chronic secondary musculoskeletal pain
Abbreviation: NP = neuropathic pain.
Table 2: The IASP classiﬁcation of chronic NP [4].
Chronic neuropathic pain
Chronic peripheral neuropathic pain Chronic central neuropathic pain
Trigeminal neuralgia Chronic central NP associated with spinal cord injury
Chronic NP after peripheral nerve injury Chronic central NP associated with brain injury
Painful polyneuropathy Chronic central poststroke pain
Postherpetic neuralgia Chronic central NP associated with multiple sclerosis
Painful radiculopathy
Abbreviation: NP = neuropathic pain.
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microvascular compression with morphological changes
(nerve atrophy or displacement) of the trigeminal nerve root
entry in the pons, as demonstrated by high-resolution 3T
MRI [6, 7]. This subtype of TN represents some 80% of the
all TN patients [9]. Secondary TN can be caused by various
neurological disorders, such as tumours in the cerebellopon-
tine angle, MS (i.e., demyelinating lesion in the pons), or an
arteriovenous malformation. Clinically, the main diﬀerence
between the classical and the secondary TN is that secondary
TN presents with sensory abnormalities in the orofacial area
innervated by the trigeminal nerve [6, 7, 10]. The last
category of TN is idiopathic, which means unknown cause
(i.e., proper diagnostic work-up does not conﬁrm any lesion
or disease as causative) [6, 7]. Idiopathic TN makes up about
11% of all TN cases [7].
The incidence of TN is from 4.3 to 27 cases per 100,000
capita per year and is more common in persons older than
60 years. Regarding the sex, TN is more frequent in women
(5.9/100,000 cases per year) than in men (3.4/100,000 cases
per year) [9].
The diagnosis of TN requires proper medical history. As
regards neurological physical examination, it should be
underlined that this type of pain can be triggered and in the
classical form, sensory disturbances are usually absent. As
for instrumental investigation, the fundamental method is
high-resolution 3T MRI, which gives us information about
the status of the posterior cranial fossa. The diﬀerential
diagnosis of TN includes other cranial neuralgias (e.g.,
glossopharyngeal neuralgia), other facial pains (e.g., persis-
tent idiopathic facial pain), primary headache disorders
(such as cluster headache or other trigeminal autonomic
cephalalgias), and odontogenic diseases such as cracked
tooth, caries, or pulpitis [11].
Treatment options of TN can be divided into a pharma-
cological and a surgical part. Pharmacological therapy
includes CBZ, OXC, lamotrigine, pregabalin, gabapentin,
baclofen, or BoNTA injection [8, 11]. Pharmacological treat-
ment recommendations are similar in the classical and
secondary forms of TN. Among these pharmacons, CBZ
and OXC (as sodium ion channel blocker antiepileptics) as
gold standards have strong recommendations as ﬁrst-line
and long-term treatment for TN [8, 11, 12]. The recom-
mended daily dose is 200-400mg for CBZ and 300-600mg
for OXC [13]. The majority (90%) of TN patients responds
well to these drugs [7]. The number needed to treat (NNT)
for CBZ is low (NNT = 1:7) [11]. Contrarily, the number
needed to harm (NNH) for CBZ is high (NNT = 24 for severe
side eﬀects and NNT = 3:4 for minor side eﬀects) [11]. The
most common adverse events of CBZ are somnolence, dizzi-
ness, drowsiness, rash, liver damage, hyponatraemia, tremor,
and ataxia [8, 11]. For TN patients who cannot tolerate the
recommended full dose of CBZ or OXC, an add-on treatment
with lamotrigine or baclofen can be advised [14]. BoNTA
represents a third-line treatment option for treating TN [2, 8].
Surgical therapeutic possibilities include microvascular
decompression (MVD), gamma knife radiosurgery, glycerol
rhizolysis, internal neurolysis, and radiofrequency thermo-
coagulation. MVD is the ﬁrst choice for drug-refractory TN
patients with neurovascular contact. Around 73% of patients
still report signiﬁcant pain relief ﬁve years after MVD
treatment [11].
2.2. Chronic NP after Peripheral Nerve Injury. This type of
pain originates from peripheral nerve lesions and can be
recurrent or persistent [4]. Based on the latest classiﬁca-
tion, “chronic NP after peripheral nerve injury” is a
third-level diagnosis of the “chronic NP” group and can
also be derived from “chronic posttraumatic pain,” an
additional parent [4, 15]. In addition, many disorders listed
in the “chronic postsurgical pain” category can be associated
with neuropathic component.
2.2.1. Chronic Postsurgical Pain Disorders with Neuropathic
Component. Chronic postsurgical pain develops after a surgi-
cal procedure. Disorders related to this special pain type are
the following: chronic pain after amputation, chronic pain
after spinal surgery, chronic pain after thoracotomy, chronic
pain after breast surgery, chronic pain after herniotomy,
chronic pain after hysterectomy, and chronic pain after
arthroplasty [15]. Most of these conditions associate with
neuropathic components in about half of the patients, which
is reﬂected also by their therapeutic options.
(1) Chronic Pain after Amputation. By deﬁnition, chronic
pain after amputation means that the pain developed after
surgical amputation of a body part (e.g., limb, breast, tongue,
teeth, genitalia, eye, or rectum) [15]. The most common
localization of chronic pain after amputation is the distal part
of the amputated limb (i.e., stump or phantom limb pain).
The prevalence of phantom limb pain is between 30 and
85% [16, 17]. Pharmacological treatment of phantom limb
pain is still unresolved, based on a recent Cochrane meta-
analysis [18]. The suggested pharmacons are N-methyl-D-
aspartate (NMDA)-receptor antagonists (e.g., ketamine and
memantine), gabapentinoids (i.e., gabapentin and pregaba-
lin), TCAs (e.g., amitriptyline), and opioids [18, 19].
(2) Chronic Pain after Spinal Surgery (Failed Back Surgery
Syndrome (FBSS)). The location of this type of pain is the site
of the operation or it can radiate to the lower extremities with
neuropathic component [15, 20]. This chronic NP develops
in an average of 20% of patient who underwent lumbar spinal
surgery [15]. From therapeutic perspective, nonsteroidal
anti-inﬂammatory drugs (NSAIDs) have only limited eﬀect;
however, the eﬃcacy of gabapentin or pregabalin has already
been proved in this type of chronic pain [20]. CBT-based
treatment has also been reported to decrease postsurgical
pain intensity [21]. In addition, spinal cord stimulation, as
a nonpharmacological treatment option, has shown beneﬁ-
cial results as well [7, 20].
(3) Chronic Pain after Thoracotomy. It is deﬁned as a pain
after surgical incision to the chest wall. The prevalence of this
type of chronic pain is about 50% of postthoracotomy
patients, whereas about one-third develops neuropathic
component as well. Optimal preemptive analgesia may give
a chance to reduce this high rate [22]. As pharmacological
treatment, gabapentin and pregabalin have shown a
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beneﬁcial eﬀect. As nonpharmacological treatment, neurax-
ial blockade or continuous paravertebral or epidural catheter
can also be used [22].
(4) Chronic Pain after Breast Surgery. Surgical procedures in
the breast area lead to the development of chronic pain in
some 25-60% of the cases [15]. From pharmacological point
of view, amitriptyline, gabapentinoids, venlafaxine, and
topical capsaicin cream, whereas as a surgical method,
autologous fat grafting have shown a signiﬁcant eﬀect in pain
alleviation [23, 24].
(5) Chronic Pain after Herniotomy. This type of chronic pain
originates from the surgical repair of an inguinal or femoral
hernia. Around 20-30% of the operated patients develop
chronic pain, and some 80% of these cases suﬀer from neuro-
pathic pain [15]. The treatment of postherniotomy chronic
pain is not yet solved. Based on a systematic review, pulsed
radiofrequency ablation as an invasive pain treatment
technique can relieve chronic postherniotomy pain [25].
(6) Chronic Pain after Hysterectomy. It can occur after the
surgical (open transabdominal, laparoscopic, or transvagi-
nal) removal of the uterus and the annexes. This type of
chronic pain aﬀects 5-32% of the operated women, with
neuropathic component being present in 5-50% of the cases
[15, 26]. Underlying the relevance of this condition, it is
estimated that 1 out of 9 women undergoes hysterectomy
in the USA [27]. Proper acute pain management during/after
hysterectomy may inﬂuence the development of this postsur-
gical chronic pain [28].
(7) Chronic Pain after Arthroplasty. Following surgical
replacement of a knee or hip joint, chronic NP develops in
some 27-38% of the operated patients [15]. Novel surgical
techniques and adequate perioperative pain management
give a chance to reduce the risk of the development chronic
pain after knee arthroplasty [29]. A multimodal approach
of perioperative pharmacological management includes the
administration of NSAIDs, acetaminophen, corticosteroids,
clonidine, ketamine, gabapentin, or pregabalin [29, 30].
2.2.2. Chronic Posttraumatic Pain Disorders with
Neuropathic Component. These types of pain disorders
develop after traumatic or burn injury of tissues, in partic-
ular, chronic pain after burn injury, chronic pain after
peripheral or central nervous system injury, whiplash
injury-associated pain, and chronic pain after musculoskele-
tal injury. After polytrauma, the frequency of the develop-
ment of chronic pain is 46-85% [15]. In the treatment of
this painful condition, pregabalin has shown strong eﬃcacy,
according to the latest Cochrane Database conclusion [31].
(1) Chronic Pain after Burn Injury. The background of this
pain condition is multicausal (heat, cold, electricity, chemi-
cal, friction, or radiation injuries). Its prevalence is around
18-52% [15]. Neither pharmacological nor nonpharmacolo-
gical therapies are well established [32]. A recently published
retrospective cohort study concluded that early gabapentin
administration for chronic pain after burn injury did not sig-
niﬁcantly diminish the pain intensity [33]. In the treatment
of complex regional pain syndrome (CRPS), a condition
caused by scarring after burn injury, the administration of
calcitonin, bisphosphonates, mirror visual feedback
treatment, and sympathetic ganglion blockade can be recom-
mended with high levels of evidence [34]. CRPS can also
result from trauma of the extremities. There are two
subtypes: CRPS I and II. In CRPS I, there is no peripheral
nerve injury, whereas in CRPS II, peripheral nerve injury is
required for the diagnosis [35].
(2) Chronic Pain after Peripheral Nerve Injury. In addition to
be a subclass of “chronic posttraumatic pain” [15], a
subgroup of this condition that is associated with NP, i.e.,
“chronic NP after peripheral nerve injury” is in fact the
parent of all pain conditions that are associated with periph-
eral NP, due to the novel multiple parenting classiﬁcation
system [4]. TCAs were found eﬃcient in the treatment of this
subtype of chronic pain [36]. In a case series of patients
with therapy-resistant brachial plexus lesion that leads to
chronic posttraumatic NP, peripheral nerve stimulation
was eﬀective [37].
2.3. Painful Polyneuropathy. Painful polyneuropathy is one
of the most common chronic NP conditions. It is a heteroge-
neous group of NP and can be divided into diabetic and
nondiabetic groups (including nondiabetic metabolic,
autoimmune, infective (especially due to Human Immuno-
deﬁciency Virus (HIV) infection), toxic, genetic, and drug-
induced) [4].
Based on data from epidemiological studies, the preva-
lence of painful diabetic polyneuropathy (PDP) is variable,
ranging from 14.1% to 65.3% [38]. Due to its high frequency,
PDP was the prototype disorder for the development of anti-
NP therapeutic strategies. The ﬁrst-line drugs in PDP as
recommended by diﬀerent international therapeutic guide-
lines are the following: duloxetine, gabapentin, pregabalin,
TCAs (amitriptyline), and venlafaxine ER (extended release)
[12, 39, 40]. Cochrane meta-analyses concluded that
gabapentin, pregabalin, and duloxetine are eﬀective for pain
relief in PDP [31, 41, 42]. The second-line recommended
pharmacons are opioids [12] and capsaicin (8%) patch [2].
The high-concentration (8%) capsaicin patch provided better
pain relief than that with a substantially lower concentration
in PDP patients [31]. BoNTA injection is recommended as a
third-line treatment in PDP [2]. As regards OXC, a Cochrane
meta-analysis concluded that it had little evidence for eﬀec-
tiveness in PDP [43]. Similarly, a systematic analysis demon-
strated that oxycodone had only very low-quality evidence to
be eﬀective in PDP [44].
As a nondiabetic painful polyneuropathy, the prevalence
of HIV-related painful neuropathy is around 35% in HIV-
positive patients and it is up to 50% of patients with Acquired
Immune Deﬁciency Syndrome (AIDS) [17]. In the treatment
of HIV-associated painful neuropathy, topical capsaicin (8%)
patch is recommended as ﬁrst-line pharmacological therapy
[12]. A recent Cochrane review analysing the eﬃcacy of preg-
abalin in HIV-related neuropathy revealed ineﬀectiveness
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[31]. The high-concentration (8%) capsaicin patch provided
better pain relief than that with a substantially lower concen-
tration in HIV-related painful neuropathy [45].
2.4. Postherpetic Neuralgia. Postherpetic neuralgia (PHN) is
deﬁned as a chronic pain lasting more than 3 months that
developed secondary to varicella zoster virus infection.
PHN involves the dermatomes innervated by the aﬀected
cranial nerve or spinal dorsal root ganglions [4]. PHN
develops in about 10% of infected patients; however, the risk
of development increases with age, with 20% of patients over
the age of 65 and 30% of those over the age of 80 developing
PHN after zoster [46]. As ﬁrst-line treatment for PHN,
gabapentin, pregabalin, TCAs, and lidocaine plaster are
recommended [12]. A Cochrane meta-analysis concluded
that gabapentin was eﬀective for pain relief in PHN [41].
Regarding pregabalin, the Cochrane Database also conﬁrmed
its eﬃcacy in PHN [31]. For second- or third-line treatment
options, capsaicin (8%) patch or opioids are recommended
[12]. The high-concentration (8%) capsaicin patch provided
better pain relief than that with a substantially lower concen-
tration of capsaicin in PHN patients [45]. A systematic meta-
analysis demonstrated that oxycodone, as a strong opioid,
had only very low-quality evidence to be useful in providing
pain relief in PHN [44]. BoNTA injection is recommended as
a third-line treatment in PHN [2].
2.5. Painful Radiculopathy. By deﬁnition, painful radiculopa-
thy is a pain that originates from a lesion or disease of the
cervical, thoracic, lumbar, or sacral nerve roots [4].
A large clinical study revealed that the majority (54.7%)
of patients suﬀering from chronic low back pain with radicu-
lopathy have neuropathic component [47]. Other authors in
Western European countries estimated this ratio to be some-
where between 20% and 35% [48, 49]. For patients suﬀering
from painful cervical or lumbar radiculopathy with neuro-
pathic component, pregabalin has been shown to be eﬀective
by certain studies [47, 50]. However, a recent randomized
controlled trial (RCT) investigating the eﬀect of pregabalin
in patients with acute and chronic sciatica reported that
pregabalin had no beneﬁt [51]. Based on a literature review,
gabapentin and nortriptyline diminished the intensity of
cervical or lumbar radicular chronic pain [52]. A recent
comprehensive review suggested TCAs and SNRIs (e.g.,
duloxetine and venlafaxine) for treatment of chronic low
back pain with neuropathic component [53]. A Cochrane
meta-analysis revealed that OXC in NP related to radiculopa-
thy had little evidence for eﬀectiveness [43].
3. Chronic Central NP
Chronic central NP is caused by a lesion or disease of the
central somatosensory nervous system. It can be related to
spinal cord or brain injury, stroke, or MS [4].
3.1. Chronic Central NP Associated with SCI. By deﬁnition,
chronic central NP associated with SCI is caused by a lesion
or disease of the somatosensory pathway in the spinal cord
[4]. This condition can also be derived from the “chronic
pain after spinal cord injury” category, referring to patients
who have neuropathic component as well [15].
The prevalence of chronic pain after SCI is estimated to
be between 40% and 70% [17]. Reﬂecting the high rate of
patient with NP within this group, ﬁrst-line pharmacological
treatments recommended by the European therapeutic
guideline for chronic pain after SCI include drugs with
antineuropathic potential, such as gabapentin, pregabalin,
and TCAs [12, 36]. A randomized, double-blind, placebo-
controlled trial (n = 40 patients) revealed that BoNTA
injection was eﬀective in pain relief compared to placebo in
intractable chronic NP in patients after SCI [54, 55]. Regard-
ing nonpharmacological interventions, exercise programme
led to mean reduction in pain intensity, whereas repetitive
transcranial magnetic stimulation (rTMS), acupuncture,
self-hypnosis, TENS, and CBT provided no evidence of
eﬃcacy in alleviating SCI-related chronic pain. Overall, based
on the data of clinical trials, evidence regarding the eﬃcacy of
nonpharmacological treatments in chronic pain after SCI is
not suﬃcient [56].
3.2. Chronic Central NP Associated with Brain Injury. By
deﬁnition, chronic central NP associated with brain injury
is caused by a lesion or disease of the somatosensory areas
of the brain [4]. This pain condition can also be derived from
“chronic pain after brain injury” category, referring to
patients with neuropathic component [15].
The estimated global yearly incidence of traumatic brain
injury (TBI) is 106/100,000 capita, whereas it is around
600/100,000 capita in the case of mild TBI [57, 58]. Some
13 million people is estimated to live with disabilities related
to TBI in Europe and the USA [59]. The most common pain
type related to mild TBI is headache, with a prevalence of
57.8%. Other frequent pain forms include neck or back pain
and musculoskeletal pain [60].
Eﬀective pain treatment after TBI may reduce the risk for
pain chroniﬁcation. For TBI-related chronic pain, topical
agents, opioids (e.g., tramadol), anticonvulsants (gabapentin
and pregabalin), and TCAs are recommended. Nerve block-
ades and epidural steroid administration may also be useful
[61]. Patients with mild TBI who were treated with rTMS
demonstrated signiﬁcantly diminished pain intensity (as
estimated by Numerical Rating Scale (NRS) and elevated
physical and mental item scores of the Short-Form- (SF-)
36 questionnaire compared to the control group) [62].
Psychological distress and posttraumatic stress are often
associated with TBI-related chronic pain. Diﬀerent psycho-
therapeutic methods can be beneﬁcial. In addition, long-
term rehabilitation should be oﬀered for these patients [63].
3.3. Chronic Central Poststroke Pain (CPSP). Poststroke pain
involves neuropathic and nociceptive mechanisms. The
neuropathic mechanism occurs in patients who have
thalamic or parietal lobe vascular lesion predominantly in
the right hemisphere [4, 64]. The prevalence of CPSP is
estimated to be between 8% and 30%, with a predominance
in young stroke patients (being twice as frequent as in older
patients) [17, 64, 65]. Typical features of CPSP are constant
or intermittent pain, hyperalgesia, and allodynia [64, 66].
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Treating CPSP is a big challenge for physicians. Management
of CPSP includes both pharmacological and nonpharmaco-
logical treatment options. The analyses of the eﬃcacy of
pharmacological treatments in CPSP concluded that TCAs
(amitriptyline) may have some beneﬁcial eﬀect. The eﬀec-
tiveness of antiepileptics (such as CBZ, gabapentin, lamotri-
gine, levetiracetam, or pregabalin) in the treatment of CPSP
is still highly questionable. The above drugs can also be used
in combinations. The role of opioids and anaesthetics in the
management of CPSP is still under debate [64–67].
Nonpharmacological treatment in CPSP includes neuro-
stimulatory techniques (such as motor cortex stimulation,
deep brain stimulation (DBS), rTMS, and psychotherapy
(e.g., CBT)). The data of these therapeutic approaches is still
inconclusive due to the lack of well-designed RCTs [64–67].
Until now, the main limitation of motor cortex stimulation
is the relatively low number of the treated patients. In addi-
tion, the eﬃcacy of motor cortex stimulation depends on
the accurate placement of the stimulation electrode. The
ﬁndings regarding the eﬀect of DBS in CPSP patients are also
variable [64–67]. The results about the eﬀectiveness of rTMS
in CPSP are disappointing [64–67].
Overall, there is no clear evidence about the eﬃcacy of
either pharmacological or nonpharmacological therapeutic
options in CPSP patients.
3.4. Chronic Central NP Associated with MS. The origin of NP
in MS depends on the localization of the lesion in the somato-
sensory system. Pain related to spasticity in MS should be
distinguished from NP, and it is a member of the subclass of
musculoskeletal pain [4]. The prevalence of NP in MS is esti-
mated to be around 23% [17]. There are no MS-speciﬁc
recommendations for the pharmacological treatment of MS-
associated chronic NP. Among the available medications,
TCAs (e.g., amitriptyline), gabapentinoids (i.e., gabapentin
and pregabalin), and SNRIs (e.g., venlafaxine and duloxetine)
can be administered. In the case of MS-associated TN, CBZ or
OXC is recommended [68, 69]. The medical use of cannabi-
noids (e.g., tetrahydrocannabinol (THC)/cannabidiol (CBD)
oromucosal spray) in chronic central NP associated with MS
might be beneﬁcial, but generally, it is still a controversial
issue due to their inconsistent results regarding their eﬃcacy
and numerous side eﬀects [2, 12, 70, 71]. Regarding neuro-
modulation in MS-related NP, the following techniques seem
to have promising eﬀects: intrathecal baclofen, functional
electrical stimulation, DBS, and spinal cord stimulation
[72]. Regarding nonpharmacological interventions, includ-
ing TENS, psychotherapy (e.g., telephone self-management
or hypnosis), transcranial random noise stimulation, trans-
cranial direct current stimulation (tDCS), hydrotherapy,
and reﬂexology, there is at present a very low level of
evidence to support their use in patients with chronic MS-
related NP, based on a recent Cochrane meta-analysis [73].
4. Therapeutic Approaches for NP
Treatment options for NP can be divided into pharmacolog-
ical and nonpharmacological (e.g., interventional, physical,
and psychological therapies) approaches.
4.1. Pharmacological Therapeutic Options for NP. The
therapeutic drug regimen for NP includes TCAs, SNRIs, anti-
epileptics, opioid analgesics, topical agents, and other drugs.
We give the quality of evidence and the strength of recom-
mendation of these pharmacons based on the Grading of
Recommendation, Assessment, Development and Evaluation
(GRADE) system [74] (Table 3).
4.1.1. First-Line Pharmacological Treatments for NP. Among
TCAs, amitriptyline (10-150mg/day) is recommended as a
ﬁrst-line drug in the treatment of all NP conditions with
strong recommendation based on moderate quality of
evidence [2, 12, 13, 36, 74, 75]. Its major side eﬀects are
related to its anticholinergic eﬀects (i.e., dry mouth, constipa-
tion, urinary retention, and orthostatic hypotension) [17, 36].
From the wide group of antiepileptics, gabapentinoids,
such as gabapentin/gabapentin ER/enacarbil (1200-
3600mg/day tid) and pregabalin (300-600mg/day bid),
are the ﬁrst-choice drugs in the treatment of all types
of NP with strong recommendation based on high quality
of evidence [2, 12, 13, 36, 74]. Regarding the latest Cochrane
conclusion, the evidence for the eﬃcacy of pregabalin in
central NP is insuﬃcient [31]. The major side eﬀects of
gabapentinoids are dizziness, sedation, and peripheral
swelling [17, 36].
CBZ (200-400mg/day) and OXC (300-600mg/day) are
recommended for TN [12, 76].
From the SNRI group, venlafaxine (150-225mg/day
once a day) and duloxetine (60-120mg/day once a day)
are the ﬁrst-choice drugs with strong recommendation
based on high quality of evidence for all NP conditions
[2, 12, 13, 36, 74]. The most common side eﬀect of SNRIs
is nausea [17, 36].
4.1.2. Second-Line Drug Treatments for NP. The opioid
analgesics tramadol/tramadol ER (200-400mg/day bid)
and tapentadol (50-600mg/day) are second-choice drugs
with weak recommendation based on moderate quality of
evidence for all types of NP [2, 12, 13, 36, 74]. The most
common side eﬀects of opioids are nausea, vomiting, and
constipation [36].
Regarding topical agents, lidocaine (5%) plaster and
capsaicin (8%) patch are recommended as second-choice
drugs in the treatment of peripheral NP. Lidocaine patches
have weak recommendation based on low quality of
evidence, whereas capsaicin patches have weak recommen-
dation based on high quality of evidence in the case of
peripheral NP. [2, 12, 13, 36, 74]. The main side eﬀects of
these topical agents are erythema and itching [36].
4.1.3. Third-Line Drug Treatments for NP. The strong
opioids, morphine (10-120mg/day) and oxycodone (10-
120mg/day), are recommended as third-line pharmacother-
apeutic options with weak recommendation based on
moderate quality of evidence for all NP conditions. The
neurotoxin, BoNTA subcutaneously (50-200 IU BoNTA in
0.9% saline every three months), is a third-choice treatment
option with weak recommendation based on low quality of
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evidence for peripheral NP [2, 12, 13, 36, 74]. The main side
eﬀect of BoNTA treatment is pain at injection site [36].
4.1.4. Other Therapeutic Options in the Pharmacological
Treatment of NP. The role of cannabis-based medicines
(herbal cannabis, plant-derived, or synthetic THC or
THC/CBD oromucosal spray) in chronic NP conditions has
not yet been established, as their potential beneﬁts and harms
are not clear [77]. Oromucosal cannabinoids might have a
beneﬁcial eﬀect in MS-related central NP and in peripheral
NP with allodynia [2]. The eﬀect of herbal medicinal prod-
ucts (e.g., nutmeg or St. John’s wort) is still controversial
according to a recent Cochrane review [78].
4.2. Nonpharmacological Therapeutic Options for NP. This
category includes interventional, physical, and psychological
therapies.
4.2.1. Interventional Therapies for NP. Interventional treat-
ments in diﬀerent types of NP management include nerve
blockades, epidural steroid injections, radiofrequency
neuroablation, and intrathecal drug delivery as minimally
invasive procedures, and peripheral and central neurostimu-
latory techniques (Table 4). Interventional treatments are
indicated in intractable NP cases.
(1) Peripheral Nerve Blockades. The target of peripheral nerve
blockades varies, depending on the aﬀected peripheral
nerves. The injected medications are local anaesthetics or
their combination with opioids, clonidine, or steroids. The
eﬃcacy of peripheral nerve blockades in NP is still inconclu-
sive [2, 79, 80].
(2) Epidural Steroid Injection. The eﬃcacy of epidural
corticosteroid (e.g., methylprednisolone, triamcinolone,
Table 3: Pharmacological therapeutic options for neuropathic pain.
Indications
Recommended
dosage
Side eﬀects Comments Ref.
First-line drugs
TCAs
All types of
NP
Amitriptyline:
10-150mg/day
Dry mouth, constipation,
urinary retention, orthostatic
hypotension
Moderate quality of evidence;
strong recommendation
[2, 12,
13, 36,
74]
Gabapentinoids
All types of
NP
Gabapentin:
300-
3600mg/day
Pregabalin: 150-
600mg/day
Dizziness, sedation,
peripheral swelling
High quality of evidence;
strong recommendation
[2, 12,
13, 36,
74]
SNRIs
All types of
NP
Duloxetine: 20-
120mg/day
Venlafaxine:
150-225mg/day
Nausea
High quality of evidence;
strong recommendation
[2, 12,
13, 36,
74]
Anticonvulsants
(sodium ion
channel blockers)
Trigeminal
neuralgia
Carbamazepine:
200-400mg/day
Oxcarbazepine:
300-600mg/day
Sedation, hepatotoxicity,
hyponatraemia
GRADE recommendation is
not applicable
[2, 12,
13, 36,
74]
Second-line drugs
Weak opioids
All types of
NP
Tramadol: 25-
400mg/day
Tapentadol: 50-
600mg/day
Nausea, vomiting,
constipation
Moderate quality of evidence;
weak recommendation
[2, 12,
13, 36,
74]
Topical agents
Peripheral
NP
Lidocaine (5%)
plaster
Capsaicin (8%)
patch
Erythema, itching
Lidocaine (5%) plaster: low quality of
evidence; weak recommendation; capsaicin
(8%) patch: high quality of evidence; weak
recommendation
[2, 12,
13, 36,
74]
Third-line drugs
Strong opioids
All types of
NP
Morphine: 10-
120mg/day
Oxycodone: 10-
120mg/day
Nausea, vomiting,
constipation
Moderate quality of evidence;
weak recommendation
[2, 12,
13, 36,
74]
Neurotoxin
Peripheral
NP
Botulinum toxin
type A
Pain at injection site
Low quality of evidence;
weak recommendation
[2, 12,
13, 36,
74]
Abbreviations: NP = neuropathic pain; SNRI = serotonin norepinephrine reuptake inhibitor; TCA = tricyclic antidepressant.
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Table 4: Nonpharmacological therapeutic options for neuropathic pain.
Indications Comments Ref.
Interventional therapies
Nerve blockade Drug-refractory NP
Local anaesthetics or combination with
opioids, clonidine, or steroids; inconclusive
recommendation
[2,
79,
80]
Epidural corticosteroid injection Drug-refractory painful radiculopathy
Methylprednisolone, triamcinolone,
betamethasone, dexamethasone; moderate
quality of evidence; weak strength of
recommendation
[2,
79,
80]
Sympathetic nerve/ganglion treatment Intractable NP Blockade, neurolysis, or neuroablation
[2,
79–
81]
Intrathecal drug delivery Drug-resistant NP Morphine, ziconotide
[2,
80,
82,
83]
Peripheral nerve/ﬁeld stimulation Intractable low back pain Subcutaneous application
[84–
87]
Transcutaneous electrical nerve stimulation
(TENS)
Intractable NP Very low level of evidence
[87–
89]
Dorsal root ganglion stimulation
Drug-refractory CRPS and causalgia of
the lower limb
High level of evidence
[87,
91]
Spinal cord stimulation (SCS)
Drug-refractory painful diabetic
neuropathy, truncal PHN, SCI-
associated NP, CPSP, FBSS with
radiculopathy, CRPS I and II
Weak recommendation
[80,
87,
92]
Epidural motor cortex stimulation Intractable NP Weak recommendation
[87,
92]
Repetitive transcranial magnetic stimulation
(rTMS) of the primary motor cortex
Intractable NP Weak recommendation
[87,
92]
Transcranial direct current stimulation
(tDCS) of the primary motor cortex
Intractable NP Weak recommendation
[87,
92]
Deep brain stimulation (DBS); repetitive
transcranial magnetic stimulation (rTMS) of
the dorsolateral prefrontal cortex;
transcranial direct current stimulation
(tDCS) of the dorsolateral prefrontal cortex
Intractable NP Inconclusive
[87,
92]
Transcranial direct current stimulation
(tDCS) of the primary motor cortex
Intractable spinal cord injury-associated
NP
Inconclusive
[87,
92]
Physical therapies
Heat and cold applications, ﬂuidotherapy,
whirlpool, massage, ultrasound, short-wave
diathermy, low-frequency currents (e.g.,
TENS, diadynamic currents and
interferential currents), high-voltage
galvanic stimulation, laser
Spinal cord injury-associated NP,
chronic postsurgical pain, painful
radiculopathies, and painful diabetic
neuropathy
Inconclusive [93]
Rehabilitation techniques (relaxation
techniques, acupuncture, mirror therapy,
graded motor imagery, visual illusion)
Spinal cord injury-associated NP,
phantom pain, CRPS, and chronic
poststroke NP
Not well-established
[2,
93]
Exercise training All types of NP Beneﬁcial eﬀect [94]
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betamethasone, or dexamethasone) injection for the
treatment of painful radiculopathy is still debated, with the
strength of recommendations ranging from weak to strong,
and the quality of evidence is moderate [2, 79, 80]. Further
studies are needed to clarify these inconsistent ﬁndings.
(3) Sympathetic Nerve or Ganglion Treatments. Sympathetic
nerve or ganglion treatments can be performed by means of
blockade, neurolysis, or ablation. The strength of recommen-
dation of the sympathetic nerve block in the treatment of
CRPS is inconclusive, and the quality of evidence is low. In
truncal PHN, the strength of recommendation for sympa-
thetic nerve blockades is against and the quality of evidence
is moderate [2, 79–81].
(4) Intrathecal Drug Delivery. To date, only two medications
(morphine and ziconotide) are applicable as intrathecal pain
therapies for diﬀerent types of chronic NP (e.g., truncal PHN,
PDN, SCI, FBSS with radiculopathy, and CRPS). Well-
designed clinical trials are still lacking. The strength of the
recommendations in all of them is inconclusive, and the
quality of evidences is low [2, 80, 82, 83].
(5) Neurostimulation. Neurostimulation is a nonpharmaco-
logical technique for the alleviation of NP. It can be divided
into peripheral or central, and noninvasive or invasive neuro-
stimulatory techniques. In the past years, several clinical
studies have been published in this ﬁeld. The diverse results
of these studies have been evaluated by the GRADE system
[2, 80, 82, 83].
(a) Peripheral Neurostimulation
(i) Peripheral Nerve/Field Stimulation. Peripheral ner-
ve/ﬁeld stimulation (subcutaneous) was eﬀective in
chronic and intractable low back pain [84–87]
(ii) TENS. The Cochrane systematic analyses concluded
that the quality of evidence regarding the usefulness
of TENS in the treatment of NP is very low [87–89]
(iii) Dorsal root ganglion (DRG) stimulation. A long-
term, one-year outcome study revealed that DRG
stimulation was eﬀective in chronic NP; the pain
was diminished by 56% at 12 months after the
implantation of the leads [90]. A recent literature
review has reported that the usefulness of DRG stim-
ulation is supported by a high level of evidence. DRG
stimulation was superior to spinal cord stimulation
(SCS) in alleviating NP in CRPS and causalgia of
the lower limb [87, 91]
(b) Central Neurostimulation. As regards the usefulness
of central neurostimulatory techniques in intractable
diﬀerent NP conditions, weak recommendations
could be established for SCS, epidural motor cortex
stimulation, rTMS of primary motor cortex, and
tDCS of primary motor cortex [87, 92]. Inconclusive
results were found for DBS, rTMS of the dorsolateral
prefrontal cortex, and tDCS of the dorsolateral
prefrontal cortex in NP and for tDCS of the primary
motor cortex in SCI-associated NP [87, 92]. SCS has
been studied in diﬀerent types of drug-refractory NP.
Based on the GRADE classiﬁcation, the strength of
recommendations of SCS in truncal PHN, PDN,
CRPS II, SCI-associated NP, and CPSP are inconclu-
sive and quality of evidences are low. In FBSS with
radiculopathy and CRPS I, the strength of recom-
mendation for SCS is weak, and the quality of
evidence is moderate [80]
4.2.2. Physical Therapies for NP. Physical therapies are
optional add-on possibilities, when pharmacological treat-
ment options do not yield not satisfactory results.
There are numerous physical therapy modalities which
can be applicable in NP, including the following: heat and
cold applications, ﬂuidotherapy, whirlpool, massage,
ultrasound, short-wave diathermy, low-frequency currents
(such as TENS, diadynamic currents, and interferential
currents), high-voltage galvanic stimulation, and laser. These
Table 4: Continued.
Indications Comments Ref.
Exercise therapy combined with
psychological therapy
Painful diabetic neuropathy Moderate eﬀect [95]
Psychological therapies
Cognitive behavioural therapy (CBT)
Chronic NP; painful diabetic
neuropathy, cancer-associated NP, HIV-
associated NP
Eﬀective in improving mood and
catastrophizing outcomes; good practice
point
[2,
96,
101]
Internet-delivered psychological therapies Nonheadache chronic pain
Similar eﬀect to that of conventional face-
to-face psychological intervention
[97]
Hypnosis
Chronic phantom limb pain, spinal cord
injury-related NP, and multiple
sclerosis-associated NP
Low level of evidence [101]
Abbreviations: CRPS = complex regional pain syndrome; HIV = human immunodeﬁciency virus; NP = neuropathic pain.
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techniques have been investigated in diﬀerent types of NP
such as SCI, chronic postsurgical pain, radiculopathies, and
PDP; however, the results are still inconclusive [93]. Regard-
ing rehabilitation techniques of NP patients, relaxation
techniques, acupuncture, mirror therapy, graded motor
imagery, and visual illusion can be used in the management
of diﬀerent forms of NP, including SCI-associated NP, phan-
tom pain, CRPS, and CPSP [2, 93]. Exercise training might be
beneﬁcial in the treatment of peripheral NP patients [94]. A
systematic review revealed that exercise therapy combined
with psychological therapy (such as mindfulness meditation,
CBT, and mindfulness-based stress reduction), aerobic
exercise (e.g., walking), and Thai Chi (as a strength-stability
exercise) showed a moderate eﬀect on the physical activity
and quality of life in patients of PDP [95].
4.2.3. Psychological Treatments for NP. One of the main aims
of psychological treatments in chronic pain conditions
(including chronic NP) is to diminish the intensity of pain,
distress, and disability and to improve mood. CBT, but not
behavioural therapy, has a weak eﬀect in alleviating chronic
pain; it has a small eﬀect on disability; however, it is eﬀective
in improving mood and catastrophizing outcomes [2, 96].
Internet-delivered psychological therapies in nonheadache
chronic pain patients showed a tendency to reduce pain,
disability, depression, and anxiety. This new method showed
a similar eﬀect to that of the conventional face-to-face
psychological intervention [97]. In chronic NP conditions
in adults, well-designed clinical studies of psychological
treatments are lacking. Two small clinical trials on CBT
and psychotherapy demonstrated insuﬃcient evidence con-
cerning its eﬃcacy and safety in chronic NP [98]. In burning
mouth syndrome (BMS) with neuropathic component, a
chronic primary pain condition, cognitive psychotherapy
has a role in the management [99]. Based on the latest
Cochrane systematic review evaluating the treatment in
BMS, there was no RCTs assessing psychological therapies
that evaluated short-term pain relief, whereas the evidence
for the eﬃcacy of psychological therapies in BMS patients
to provide long-term symptom relief is of very low quality
[100]. Hypnosis was given low grades of recommendations
in the treatment of chronic phantom limb pain, SCI-related
NP, and MS-associated NP. The recommendation of CBT
in PDP and NP associated with cancer or HIV patients was
graded as a good practice point (GPP) [101].
5. Conclusion
The peripheral and central NP conditions have high preva-
lence and have a deep impact on the quality of life of the
patients. Alleviating this devastating pain condition is
challenging for healthcare professionals. The novelty of this
present review is the integration of the latest IASP classiﬁca-
tion of chronic pain with the International Classiﬁcation of
Diseases (ICD-11), ﬁrst in the literature. Overviewing the last
10 years of relevant literature, we highlight that there are no
speciﬁc drugs for the treatment of either peripheral or central
NP. In this ﬁeld, a major improvement is that the Neuro-
pathic Pain Special Interest Group (NeuPSIG) of the IASP
has developed a grading system in order to guide drug selec-
tion for the good clinical practice. A real breakthrough
regarding nonpharmacological therapeutic options for NP
conditions in the last decade is that clinical trials have been
conducted, meta-analyses have been published, and guide-
lines have been released.
In the near future, the development of personalized and
NP subtype-speciﬁc treatments are needed. In intractable
NP cases, invasive nonpharmacological therapeutic options
can be chosen; however, further high-quality clinical trials
are necessary.
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